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Thienorphine (TNP) is a novel partial opioid agonist that has completed phase II clinical
evaluation as a promising drug candidate for the treatment of opioid dependence.
Previous studies have shown that TNP and its glucuronide conjugate (TNP-G) undergo
significant bile excretion. The purpose of this study was to investigate the roles of efflux
transporters in regulating biliary excretion and plasma exposure of TNP and TNP-G. An
ATPase assay suggested that TNP and TNP-G were substrates of P-gp and MRP2,
respectively. The in vitro data from rat hepatocytes showed that bile excretion of TNP and
TNP-G was regulated by the P-gp and MRP2 modulators. The accumulation of TNP and
TNP-G in HepG2 cells significantly increased by the treatment of mdr1a or MRP2 siRNA
for P-gp or MRP2 modulation. In intact rats, the bile excretion, and pharmacokinetic
profiles of TNP and TNP-G were remarkably changed with tariquidar and probenecid
pretreatment, respectively. Tariquidar increased the Cmax and AUC0-t and decreased
MRT and T1/2 of TNP, whereas probenecid decreased the plasma exposure of TNP-G
and increased its T1/2. Knockdown P-gp and MRP2 function using siRNA significantly
increased the plasma exposure of TNP and TNP-G and reduced their mean retention time
in mice. These results indicated the important roles of P-gp and MRP2 in hepatobiliary
excretion and plasma exposure of TNP and TNP-G. Inhibition of the efflux transporters
may affect the pharmacokinetics of TNP and result in a drug-drug interaction between
TNP and the concomitant transporter inhibitor or inducer in clinic.
Keywords: thienorphine, multidrug resistance-associated protein 2, P-glycoprotein, biliary excretion, siRNA, drug
interaction
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INTRODUCTION
Opioid abuse and dependence remains a serious worldwide
health problem. Opioid partial agonists have been proven
to be effective in reducing illicit opioid use and exhibit a
good safety profile, particularly with respect to lowering
the respiratory depression, and dependence potential when
compared to the full µ-agonist. Thienorphine (TNP), N-
Cyclopropylmehtyl-7α-[(R)-1-hydroxyl-1-methyl-3-(thien-2-yl)
propyl]-6, 14-endoethanotetrahydronooripavine, was
synthesized as a ramification of buprenorphine, and identified
to be a novel non-selective opioid partial agonist (Liu et al.,
2005; Yu et al., 2006). When compared with buprenorphine,
TNP showed high binding affinity with the µ-opioid receptor
in vitro and a better oral bioavailability in vivo (Li et al., 2007;
Yu et al., 2013). TNP was developed for the treatment of opioid
dependence. Recently, the phase II clinical trial was completed,
and the result was positive.
The absorption, distribution, metabolism, and excretion of
TNP have been studied in pre-clinical animals (Kong et al.,
2007). TNP was extensively metabolized in the liver and gut
to form a number of oxidative and conjugated metabolites.
Glucuronide conjugate (TNP-G) was the major active metabolite
in the circulation of both rat and dog models, with weaker
pharmacological effects than TNP. TNP underwent a significant
biliary clearance in rats with nearly 24% of the oral dose excreted
from bile within 24 h. Excreted TNP and TNP-G via bile could be
reabsorbed rapidly from the rat intestine to form enterohepatic
circulation (EHC), which was confirmed using a paired rat model
and in situ perfused rat intestinal preparations (Deng et al., 2010).
EHC may prolong the pharmacologic effect of a compound
by maintaining the therapeutic concentrations for an extended
period of time (Bi et al., 2006; Shitara and Sugiyama, 2006). The
significant EHC of TNP and TNP-G was believed to be one of the
main contributors to the long-acting effect of TNP.
Drug transporters are membrane proteins that have a major
impact on the absorption, distribution, and elimination of a
wide range of drugs. They are distributed and expressed in
many tissues including the intestine, liver, kidney, and brain. In
particular, hepatic drug transporters contribute significantly to
the hepatic exposure, and biliary excretion of various endogenous
and exogenous compounds (Tchaparian et al., 2011; Kong et al.,
2015a). P-glycoprotein (P-gp), multidrug resistance-associated
protein 2 (MRP2) and breast cancer resistance protein (BCRP)
are hepatic eﬄux transporters responsible for the hepatobiliary
excretion of drugs. They extrude substrates into the bile and
restrict the (re)uptake of substrates from the gut (Sai, 2005).
Preclinical and clinical studies have demonstrated that inhibition
or induction of these transporters may influence the clearance
and pharmacokinetics of drugs and lead to altered toxicity or
Abbreviations: TNP, thienorphine; TNP-G, thienorphine glucuronide conjugate;
EHC, enterohepatic circulation; MDR1, multidrug resistance protein 1; P-
gp, P-glycoprotein; MRP2, multidrug resistance-associated protein 2; BCRP,
breast cancer resistance protein; DDIs, drug-drug interactions; BDC, bile-
duct cannulated; SCRH, sandwich-cultured rat hepatocyte; LC-MS/MS, liquid
chromatography coupled to tandem mass spectrometry; BEI, biliary excretion
index; AUC, area under the plasma concentration time curve; MRT, mean resident
time.
therapeutic efficacy (Zhuang et al., 2013; Kong et al., 2015a).
Therefore, it has become critically important to characterize a
drug candidate as a substrate or regulator of transporters during
drug development (Giacomini et al., 2010). As a promising
agent for treatment of opioid abuse, TNP has a great chance
for coadministration with other clinical drugs, such as anti-virus
drugs, and anti-inflammatory drugs. Some of these drugs are
known substrates or regulators of drug enzymes or transporters
(Kimoto et al., 2012). Concomitant use of TNP with these drugs
may result in drug-drug interactions (DDIs).
The membrane transport of TNP was previously investigated
using a Caco-2 monolayer model, and the results suggested that
eﬄux of TNPmight associate with the active transport process (Li
et al., 2010). A screening study using an ATPase assay indicated
that TNP and TNP-G were the substrates of P-gp and MRP2,
respectively. Since substantial portion of TNP excreted from bile
in rats, it is speculated that canalicular eﬄux may be involved in
the biliary excretion of TNP and its metabolites. Based on the
fact that biliary excretion and EHC contribute remarkably to the
prolonged pharmacological activity, it is necessary to investigate
the roles of eﬄux transporters in the pharmacokinetics of TNP
and assess the DDI potential of transporter modulation. In
the present study, the effects of transporter modulators on
biliary excretion and pharmacokinetics of TNP and TNP-G were
determined in sandwich-cultured rat hepatocytes (SCRH), bile-
duct cannulated (BDC), and intact rats. Chemically synthesized
small interfering RNA (siRNA) was also used to specifically
knockdown P-gp or MRP2 gene expression in Human liver
hepatocellular carcinoma cells (HepG2) and mice to further
assess the role of transporters on hepatobiliary elimination of
TNP and its metabolites.
MATERIALS AND METHODS
Materials
Thienorphine hydrochloride (99.5% in purity, Figure 1) and
thienorphine-3-glucuronide (99% in purity, Figure 1) were
synthesized using the chemical synthesis laboratory of the
Institute. Tariquidar, propranolol, verapamil, probenecid,
quercetin, dexamethasone, methotrexate, and collagenase were
purchased from Sigma (St. Louis, MO, USA). MDR1, MRP2 and
BCRP membranes as well as an ATPase assay kit were purchased
from BD Gentest Co. (Woburn, MA). Acetonitrile was of HPLC
grade (J&K Chemical LTD), and other reagents were all of an
analytical grade.
Animals
Male SD rats (weight, 220–260 g) andmale BALB/Cmice (weight,
18–22 g) were supplied by the Beijing Experimental Animal
Center (Beijing China). All animals were maintained on a 12 h
light/dark cycle with free access to water and lab chow. All of
the animal experiments were conducted at the Beijing Center for
Drug Safety Evaluation following the protocol of the Institutional
Animal Care and Use Committee of the Center.
ATPase Screening Assay
The ATPase assay was performed using an ATPase assay kit
following the instruction manual. Verapamil, probenecid, and
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FIGURE 1 | The chemical structure of TNP and TNP-G.
sulfasalazine were tested as model substrates of MDR1, MRP2,
and BCRP, respectively. The stimulated ATPase activities were
calculated by dividing the amount of inorganic phosphate
produced by the incubation time and the amount of protein used
in the incubation.
Culture of Rat Hepatocytes
Rat hepatocytes were isolated with a two-step perfusion method
as reported previously (Shen et al., 2014). Hepatocyte suspensions
were added to the precoated dishes at a density of 0.5
× 106 cells/well on 24-well plates and allowed to attach for 4 h, at
which time the medium was aspirated to remove any unattached
cells and fresh medium was added. Twenty-four hours later, cells
were overlaid with BD Matrigel at a concentration of 0.25mg
ml−1 in 0.5ml of ice-cold DMEM-F12. The hepatocytes were
cultured for 4 days, and the medium was changed daily.
Bile Clearance Study in SCRH
On day 5, SCRH were rinsed twice and then preincubated for 30
min at 37◦C with 0.5ml of warmed Hanks’ balanced salt solution
(HBSS) containing Ca2+/Mg2+ (standard buffer) to maintain
or Ca2+/Mg2+-free buffer to disrupt the tight junctions sealing
the bile canalicular networks. For the bile clearance study, the
SCRH were incubated with 20 µM TNP in HBSS at 37◦C for 2,
5, 10, 20, 30, or 60min or with 20 µM TNP-G for 5–120min.
To investigate the effect of inhibition on bile clearance, the
P-gp inhibitors, verapamil (10, 50, or 100 µM) or tariquidar (0.5,
2.5, or 5 µM), or MRP2 inhibitors, probenecid (10, 50, or 100
µM) or methotrexate (10, 50, or 100 µM), were preincubated
for 30min with the SCRH prior to the bile clearance study. To
assess the effect of induction, on day 3 to day 5 the SCRH was
replaced with fresh culture media containing the P-gp inducer
quercetin (3, 15, or 30 µM), or MRP2 inducer dexamethasone
(10, 50, or 100 µM) every 24 h. After co-incubation with TNP or
TNP-G for 60min, the supernatant was aspirated from the cells
and uptake was stopped by washing the cells three times with
ice-cold HBSS. The cells were then lysed and stored at −80◦C.
The samples were analyzed using liquid chromatography coupled
with tandem mass spectrometry (LC-MS/MS). The total protein
concentration of cell lysates was quantified using the BCA assay.
Cell Culture and Uptake Experiment in
HepG2 Cells Transfected with siRNA
HepG2 cells were obtained from the ATCC and maintained in
DMEM that was supplemented with 10% fetal bovine serum,
penicillin (100 U/ml) and streptomycin (100 µg/ml). Cells were
seeded into 24-well plates at a density of 1 × 105 cells/well and
cultured for 24 h. Transfection was performed in Opti-MEM
(Invitrogen, Carlsbad, CA, USA) with synthetic siRNA (80 pM)
by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
for 6 h, and the medium was replaced with fresh DMEM. This
condition was optimized in our previous study based on the
transfection efficiency and cellular viability (Kong et al., 2015b).
Following incubation for 48 h, the cells were washed three times
with phosphate-buffered saline buffer (PBS), and then 20 µM
TNP, or TNP-G was added to the DMEM and incubated for
5, 15, 30, or 60min at 37◦C. After incubation, the supernatant
was aspirated from the cells, and the uptake was stopped by
washing the cells three times with ice-cold PBS. The cells were
lysed and stored at −80◦C. The samples were analyzed using
liquid chromatography coupled with tandem mass spectrometry
(LC-MS/MS).
Biliary Excretion and Pharmacokinetic
Studies in Rats
Bile-duct cannulated (BDC) rats were surgically prepared as
previously reported. The BDC rats were divided into three
groups. The control group was intravenously injected with
saline 15 min prior to an intragastric dose of TNP (12mg/kg).
The two treatment groups were intravenously given probenecid
(200mg/kg) or tariquidar (10mg/kg) 15min prior to the TNP
oral dose. The bile samples were collected at the time intervals
of 0–1, 1–2, 2–4, 4–6, 6–8, 8–12, 12–24, 24–36, 36–48, and 48–
60 h. The pharmacokinetic study was performed in intact rats
following the same dose above. Blood samples (200 µl) were
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collected at 5, 15, and 30min and 1, 2, 4, 6, 8, 12, and 24 h post-
TNP dose. The plasma was separated and stored at −80◦C until
analysis.
Pharmacokinetics of TNP and Its
Metabolites in Mice Treated with siRNA
The pharmacokinetic study in mice treated with siRNA was
conducted according to our previously reported study (Kong
et al., 2015a). Mice were divided into three groups to collect the
blood samples: (1) TNP + NC-siRNA group; (2) TNP +mdr1a
siRNA group; (3) TNP + MRP2 siRNA group. The siRNA
treatment groups were intravenously injected with NC-siRNA,
MRP2 siRNA, or mdr1a siRNA 2 days prior to receiving the TNP
oral dose. Blood samples were collected at 5, 15, and 30min and 1,
2, 4, 6, 8, and 12 h after the TNP dosing. The plasmawas separated
and stored at−80◦C until analysis.
LC-MS/MS Analysis of TNP and TNP-G
The concentration of TNP and TNP-G in cells, plasma and
bile samples were analyzed according to a previously reported
method (Kong et al., 2007). An Aglient 6410B triple quadrupole
mass spectrometer equipped with the Agilent1290 Infinity
UHPLC system (Agilent Technologies, Santa Clara, CA) was
used. TNP, TNP-G, and propranolol (an internal standard)
were eluted from an Agilent C18 column with a mobile
phase consisting of equal volumes of 0.1% formic acid in
a 5mM ammonium formate solution and 0.1% formic acid
in acetonitrile. Quantification was performed using selected
reaction monitoring with the transitions of m/z 522-m/z 97,
m/z 698-m/z 522.4, and m/z 260-m/z 116.2 for TNP, TNP-G,
and propranolol, respectively. The samples were pretreated with
3-fold volume of methanol-acetonitrile (1:1, v/v), containing
20 ng ml−1 propranolol to precipitate the proteins and then
centrifuged at 4◦C at 14,000 × g for 10min. The supernatant
(10 µl) was injected into the LC-MS/MS for analysis. The lower
limit of quantification was 0.1 ng/ml for TNP, and TNP-G, and
the standard curves ranged from 0.1 to 1000 ng.
Data Analysis
The biliary excretion index (BEI) and in vitro intrinsic biliary
clearance (CLbile, int, ml/min/kg) were calculated based on the
published equations (Liu et al., 1999b):
BEI = (Accumulationcell + bile − Accumulationcells)
/Accumulationcell + bile × 100% (1)
CLbile, int = (Accumulationstandard − AccumulationCa2+/Mg2+-free)
/incubation time× concentration (medium)
× 200× 40 (2)
Drug concentrations in the medium were defined as the initial
substrate concentration in the incubation medium. The CLbile,int
was scaled to kilograms of body weight assuming the following:
200mg protein g−1 rat liver tissue and 40 g rat liver tissue kg−1
body weight (Liu et al., 1999a).
The predicted in vivo CLbile,pred values were estimated
according to the equations below (Nakakariya et al., 2012):
CLbile, pred = Qp × in vitro CLbile, int/(Qp + in vitro CLbile, int)
(3)
where Qp represents the hepatic plasma flow rate (40ml/min/kg).
In Equation (3), the plasma unbound fraction (fu,p) was assumed
to be unity. Taking into consideration the unbound fraction, the
following Equation (4) was applied:
CLbile, pred = Qp× fu, p × in vitro CLbile, int
/(Qp+ fu, p × in vitro CLbile, int) (4)
The observed in vivo biliary clearance (CLbile, obs, ml/min/kg)
was calculated according to Equation 5:
CLbile, obs = Bile Accumulation Amount0–24 h/AUC0–24 h (5)
where Amount0–24 h represents the cumulative amount of
compounds recovered in the bile from 0 to 24 h, and AUC0–24 h
represents the area under the plasma concentration-time curve
from 0 to 24 h.
All of the data were expressed as the mean ± SD. Differences
between groups were compared by Student’s t-test for analysis of
unpaired data or one-way ANOVA. The statistical significance
was accepted at P < 0.05.
RESULTS
Identification of Efflux Transporters
Associated with TNP and TNP-G
To identify the transporters responsible for TNP and TNP-G
biliary eﬄux, the ATPase screening assay was conducted.
The results (Table 1) demonstrated that the ATPase activity
of the MDR1 membrane was significantly increased by both
verapamil and TNP (from 4.3 ± 0.9 to 31.8 ± 0.7, and 19.3 ±
0.3 nmol/min/mg), but not TNP-G. The ATPase activity of
the MRP2-expressing membrane was significantly increased by
probenecid and TNP-G (from 1.2 ± 0.5 to 5.7 ± 0.2 and 4.1 ±
0.6 nmol/min/mg). The model substrate sulfasalazine enhanced
TABLE 1 | Identification of efflux transporters associated with TNP and
TNP-G.
Vanadate-sensitive ATPase activities (nmol/min/mg)
Compound MDR1 Compound MRP2 Compound BCRP
Blank 4.3± 0.9 Blank 1.2± 0.5 Blank 6.4±1.7
Verapamil 31.8± 0.7## Probenecid 5.7± 0.2## Sulfasalazine 32.2±1.3##
TNP 19.3± 0.3## TNP 0.8± 0.2 TNP 5.9±0.8
TNP-Glu 4.2± 0.8 TNP-Glu 4.1± 0.6## TNP-Glu 5.8±0.8
MDR1, MRP2, or BCRP membranes and TNP or TNP-G (1mM for MDR1, and BCRP, 30
mM for MRP2) were pre-incubated for 5 min (MDR1 and MRP2), or 10 min (BCRP). The
reactions were started by addition of 50 mM MgATP, followed by incubation at 37◦C for
20 min for MDR1, 40 min for MRP2, or 30 min for BCRP. Verapamil (1 mM), probenecid
(100 mM), and sulfasalazine (1 mM) were as model substrates, respectively. Data are
expressed as mean ± SD (n = 3). ##P < 0.01 compared with blank.
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the ATPase activity in the BCRP study, but this was not observed
for either TNP or TNP-G incubation. The results indicated that
TNP was a substrate of MDR1 and that TNP-G was a MRP2
substrate. BCRP may not be involved in the eﬄux clearance of
TNP and TNP-G.
Cell Accumulation and Biliary Excretion of
TNP and TNP-G in SCRH
The time-dependent intracellular accumulation of TNP and
TNP-G in SCRH incubated in standard HBSS or Ca2+/Mg2+-
free buffer was shown in Figures 2A, 3A. At each time point,
the cell accumulation in the standard buffer (cell+bile) was
significantly higher than that in Ca2+/Mg2+-free HBSS (cells
only), indicating excretion of TNP and TNP-G in the bile
canalicular network. The average BEI for TNP after a 60min
incubation was 14.5 ± 0.9 and 41.4 ± 2.6 for TNP-G after
a 120-min incubation. The CLbile, int of TNP and TNP-G was
5.8 ± 0.5 and 11.2 ± 2.7 ml/min/kg (Supplementary Table
1). The in vivo CLbile, pred values were predicted, based on
the total concentration (Equation 3) or the plasma unbound
fraction (Equation 4), to be 5.0 ± 0.4, or 0.3 ± 0.02ml/min/kg
for TNP and 8.7 ± 1.7 or 0.2 ± 0.01ml/min/kg for TNP-G
(Supplementary Table 1).
P-gp Mediated TNP Bile Clearance in
SCRH
Based on the ATPase assay results, known P-gp inhibitors and an
inducer were chosen to further assess the role of this transporter
in the TNP canalicular eﬄux in SCRH. Figures 2B,C show that
the known P-gp inhibitors (tariquidar and verapamil) could
reduce the BEI of TNP in a dose-dependent manner. Tariquidar
(5 µM) and verapamil (100 µM) significantly decreased the BEI
to 34.5 and 42.4% of the control cells. The CLbile, int of TNP
was reduced to 83.1 and 73.7% by tariquidar and verapamil,
respectively, (Supplementary Table 2). After pretreatment for 3
days with a dose of 30µMquercetin, a P-gp inducer, the BEI, and
FIGURE 2 | The biliary excretion of TNP in SCRH. TNP (20 µM) was added after pre-incubation of SCRH with standard buffer or Ca2+/Mg2+-free buffer for
30min to investigate the accumulation of TNP in SCRH. The inhibitors were pre-incubated with SCRH for 30min, and the inducer was pre-incubated with SCRH for
3 days before being co-incubated with TNP (20 µM) for an additional 60min. Samples were collected at different time points. Data are presented as the mean ± SD
(n = 3). #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the control group. (A) The accumulation of TNP in SCRH; (B) The effect of tariquidar on BEI of
TNP; (C) The effect of verapamil on BEI of TNP; (D) The effect of quercetin on BEI of TNP.
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FIGURE 3 | The biliary excretion of TNP-G in SCRH. TNP-G (20 µM) was added after pre-incubation of SCRH with standard buffer or Ca2+/Mg2+-free buffer for
30min to investigate the accumulation of TNP-G in SCRH. The inhibitors were pre-incubated with SCRH for 30min, and the inducer was pre-incubated with SCRH for
3 days before being co-incubated with TNP-G (20 µM) for an additional 60min. Data are presented as the mean ± SD (n = 3). #P < 0.05, ##P < 0.01, ###P <
0.001 compared with the control group. (A) The accumulation of TNP-G in SCRH; (B) The effect of probenecid on BEI of TNP-G; (C) The effect of methotrexate on
BEI of TNP-G; (D) The effect of dexamethasone on BEI of TNP-G.
CLbile, int of TNPincreased to 2.1- and 1.7-fold compared with
the control (Figure 2D, Supplementary Table 2).
MRP2 Mediated Bile Excretion of TNP-G in
SCRH
As shown in Figures 3B,C, dose-dependent inhibition of biliary
excretion of TNP-G was observed after pretreatment with the
inhibitors. At the concentration of 100 µM, probenecid and
methotrexate remarkably reduced the BEI to 22.8 and 20% of
the control cells. The CLbile, int was decreased by 78.1 and 74.2%
at the same inhibitory concentration. When pre-incubated for 3
days with dexamethasone (100 µM), a MRP2 inducer, the BEI,
and CLbile, intof TNP-G were increased up to 2.6- and 2.7-fold
(Figure 3D, Supplementary Table 3).
Effects of siRNA on the Intracellular
Concentration of TNP and TNP-G in HepG2
Cells
To further investigate the roles of P-gp or MRP2 in the
cellular uptake of TNP and TNP-G in vitro, mdr1a siRNA,
or MRP2 siRNA was used to knock down the transporter
expression in HepG2 cells. As shown in Figure 4, the intracellular
concentration of TNP and TNP-G increased in a time-dependent
manner. Compared with the NC-siRNA group, the eﬄux of TNP
and TNP-G were significantly inhibited by mdr1a siRNA and
MRP2 siRNA, respectively, and the intracellular concentrations
were increased 1.9- and 2.1-fold. In addition, the intracellular
concentration of TNP-G and TNP was not impacted by mdr1a
siRNA and MRP2 siRNA, respectively. This result further
indicated that P-gp and MRP2 play a role in transportation of
TNP or TNP-G.
Biliary Excretion in BDC Rats
The transporter mediated biliary excretion of TNP and TNP-G
was further assessed in BDC rats using transporter inhibitors.
As shown in Figure 5, TNP-G was the predominant component
detected in the bile of the control group, with a 24 h recovery
up to 28% of the TNP dose applied. The biliary excretion of
TNP was minor, amounting to less than 1% of the dose. In the
group of TNP co-administered with tariquidar (10mg/kg), the
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FIGURE 4 | Effects of siRNA on TNP and TNP-G accumulation in HepG-2 cells. HepG-2 cells were transfected with siRNAs. After 48 h, TNP, or TNP-G (20µM)
was added, and samples were collected at different time points. Data are presented as the mean ± SD (n = 3). #P < 0.05, ##P < 0.01 compared with the
NC-siRNA group. (A) Effect of mdr1a siRNA on TNP accumulation; (B) Effect of mdr1a siRNA on TNP-G accumulation; (C) Effect of MRP2 siRNA on TNP-G
accumulation; (D) Effect of MRP2 siRNA on TNP accumulation.
inhibitor significantly decreased the cumulative bile excretion
of TNP to 45% of the control level. Similarly, the remarkable
reduction of TNP-G biliary excretion by probenecid (200 mg/kg)
was observed, with the 24 h excretion rate being decreased to
74% of the control level. In addition, the in vivo CLbile, obs
was calculated using Equation 5. The CLbile, obs of TNP and
TNP-G was 2.4 ± 0.1 and 6.9 ± 0.5 ml/min/kg, respectively,
(Supplementary Table 1).
Effects of Chemical Inhibitors on TNP and
TNP-G Pharmacokinetics in Rats
To evaluate the effect of transporter modulation on TNP
pharmacokinetics, the plasma concentration-time curve of TNP
and TNP-G was obtained in rats with or without inhibitors
(Figures 6A,B). After a single oral dose of 12 mg/kg, the TNP
curve for the control group showed a second peak at 6 h, but not
for TNP-G. This indicated existing EHC from TNP in rats. When
co-administered with tariquidar, the plasma exposure (Cmax and
AUC0-t) was significantly increased, and the elimination of TNP
(T1/2 and MRT) was remarkably reduced (Table 2). In contrast,
the plasma exposure of TNP-G was remarkably reduced by the
concomitant dose with probenecid. The plasma elimination of
TNP-G was decreased with increased T1/2 and MRT.
Effects of siRNA on TNP and TNP-G
Disposition in Mice
To validate the changes observed in rats treated with chemical
inhibitors, pharmacokinetics studies in mice treated with
siRNA were further conducted. The plasma concentration-time
profiles of TNP and TNP-G were shown in Figures 6C,D.
The pharmacokinetic parameters were calculated and listed
in Table 3. As expected, treatment with the mdr1a siRNA
significantly increased the TNP plasma exposure, with the Cmax
increasing from 38.0 ± 12.6 of the control group to 211.9 ± 61.3
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FIGURE 5 | Effect of tariquidar or probenecid on biliary excretion of TNP and TNP-G in rats. Tariquidar (10mg/kg) or probenecid (200mg/kg) was injected
into the caudal vein 15min prior to the intragastric administration of TNP at a dose of 12mg/kg. Bile samples were collected at scheduled time intervals. Data are
presented as the mean ± SD (n = 6). (A) The effect of tariquidar on biliary excretion of TNP; (B) The effect of probenecid on biliary excretion of TNP-G.
ng/ml of the siRNA group and the AUC from 209.64 ± 40.5 to
708.6± 108.3 ng·h/ml. In the MRP2 siRNA group, a comparable
change was also noted for TNP-G, with Cmax increasing from
37.1 ± 14.9 to 100.2 ± 17.6 ng/ml and the AUC from 108.4 ±
19.6 to 202.7± 70.7 ng·h/ml.
DISCUSSION
The drugs currently in clinical use for treating opioid
dependence include the full-opioid agonist (methadone), partial-
opioid agonist (buprenorphine), and antagonist (naltrexone)
(O’Connor and Fiellin, 2000; Johnson et al., 2003). Although
these drugs have been proven to be extremely effective in
reducing illicit opioid use, they have some drawbacks, such
as low oral bioavailability and the potential of dependence.
Thus, compounds with a higher oral bioavailability and
lower dependence liability would be more useful for the
treatment of opioid abuse (Li, 2008). TNP, a new partial
opioid agonist, has been selected and developed for the
treatment of drug dependence. The obvious advantages of TNP
over buprenorphine, more potent, longer acting, higher oral
bioavailability, and lower dependence liability, make TNP a
promising drug candidate (Yu et al., 2006). Previous studies
suggest that the prolonged effect of TNP is likely associated with
its pharmacokinetic properties. The elimination of TNP from
plasma is slow, as its excretion can last for∼2 weeks (Kong et al.,
2007; Deng et al., 2012). Relatively low plasma concentration and
slower elimination are considered to be the desired properties
for drugs used in the treatment of opioid dependence, thereby
reducing the dose frequency and increasing the compliance of
patients (Yu et al., 2006; Kong et al., 2007).
In the present study, we present evidence that P-gp andMRP2
are involved in the biliary clearance of TNP and TNP-G. The
ATPase assay with transporter membranes indicated that TNP
was a P-gp substrate and its TNP-G was a MRP2 substrate.
In Caco-2 monolayer transport, P-gp and MRP2 inhibitors
cyclosporine A and MK571 increased the apparent permeability
of TNP, suggested that it is a substrate of P-gp and MRP2 (Li
et al., 2010). To further assess the role of transporters in cellular
accumulation, we conducted the uptake experiments in HepG2
cells treated with siRNA. Knockdown of the P-gp gene by mdr1a
siRNA significantly increased the intracellular concentration of
TNP only, and the MRP2 siRNA treatment solely increased the
TNP-G concentration. This results confirmed the findings from
ATPase assay.
An in vitro study using the SCRH model was then conducted
to confirm the transporter mediated canalicular eﬄux. SCRH
forms intact bile canalicular networks and maintains functional
expression of the transport proteins for several days (Liu et al.,
1999b; Hoffmaster et al., 2004). This model has been widely
used to assess drug uptake and eﬄux, DDIs, and hepatotoxicity
(Kimoto et al., 2012; Zhuang et al., 2013). The results of the
SCRH study demonstrated that P-gp played significant role in
the biliary excretion of TNP. The canalicular eﬄux of TNP was
remarkably affected by P-gp inhibitors or inducers. In the case
of TNP-G, MRP2 was responsible for its biliary excretion, and
similar effects were observed when SCRH was co-incubated with
the MRP2 inhibitor or inducer. The involvement of P-gp and
MRP2 in the biliary excretion of TNP and its conjugate was
further confirmed in the BDC rats. The cumulative bile excretion
of TNP and TNP-G was significantly inhibited by tariquidar and
probenecid, respectively.
In vitro-in vivo extrapolation (IVIVE) by utilizing CLbile, int
obtained from SCRH has become a common approach to predict
the in vivo biliary clearance of drugs (Nakakariya et al., 2012;
Zou et al., 2013; Pfeifer et al., 2014). The in vivo CLbile, pred of
some marketed drugs and new chemical entities predicted from
CLbile, int in SCRH or sandwich-cultured human hepatocytes
(SCHH) showed a reasonable correlation with the in vivo
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FIGURE 6 | Effect of chemical inhibitors and siRNA on pharmacokinetics of TNP and TNP-G in rats and mice. Tariquidar (10mg/kg) or probenecid
(200mg/kg) was injected into the caudal vein 15 min prior to the intragastric administration of TNP at a dose of 12mg/kg. siRNA (15 nM) was injected into the caudal
vein 2 days prior to the intragastric administration of TNP at a dose of 12mg/kg. Blood samples were collected at scheduled time intervals. Data are presented as the
mean ± SD (n = 6). (A) The effect of tariquidar on pharmacokinetics of TNP in rats; (B) The effect of probenecid on pharmacokinetics of TNP-G in rats; (C) The effect
of mdr1a siRNA on pharmacokinetics of TNP in mice; (D) The effect of MRP2 siRNA on pharmacokinetics of TNP-G in mice.
CLbile, obs (Ghibellini et al., 2007; Abe et al., 2008, 2009; Fukuda
et al., 2008). In our study, the CLbile, pred values of TNP and TNP-
G obtained from SCRH based on the plasma total concentration
was ∼2- and 1.3-fold, respectively, of the measured CLbile, obs
in rats. The CLbile, pred values calculated from Equation (4),
by taking into consideration the unbound fraction, were ∼7-
to 30-fold lower than CLbile, obs, which is a reasonable range
when compared with the data in the literature (Abe et al.,
2008, 2009). The IVIVE using data from the SCRH model in
combination with the bile excretion data from BDC rats may
provide important information for an improved understanding
of the mechanism underlying the hepatobiliary clearance of
TNP. However, further studies using SCHH are needed, as some
researchers suggested that the SCHH were more suitable for in
vitro prediction of human clearance (Abe et al., 2008).
The impact of transporter modulation on plasma
pharmacokinetics of TNP and TNP-G was further investigated
by co-administration of P-gp or MRP2 inhibitors in rats or by
pretreatment with siRNA in mice. When compared with the
control group, significant increase of TNP plasma exposure was
observed in the tariquidar treated group, with a 2.9-fold increase
in the Cmax and 3.1-fold increase in the AUC. Treatment
of mdr1a siRNA in mice increased Cmax and AUC by 5.6
and 3.4-fold, respectively, as compared to the control group.
The remarkably increased Cmax could be associated with
the inhibition on P-gp protein allocated at intestinal epithelia
(Giacomini et al., 2010). In present study, several folds of
Cmax and AUC changes in mice after siRNA treatment also
indicated that siRNA not only effected the biliary excretion,
but significantly impacted the absorption of TNP. In addition
to the changes of TNP plasma exposure, the elimination T1/2,
and MRT were significantly reduced in both tariquidar and
mdr1a siRNA treated group when compared to the control
group, indicating that the clearance of the drug was notably
increased. This was likely the result of reduced biliary excretion
and interrupted EHC of TNP and TNP-G. EHC occurs by bile
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TABLE 2 | Pharmacokinetic parameters of TNP and TNP-G after
administration of TNP to rats pretreated with tariquidar or probenecid.
TNP TNP + saline TNP + probenecid TNP + tariquidar
T1/2 (h) 7.8±1.4 5.6± 2.6 3.4±1.7
#
Cmax (ng/ml) 16.2±7.8 24.2± 3.8 47.3±8.1
#
AUC(0-t) (ng.h/ml) 38.9±23.8 39.5± 16.8 119.0±68.6
#
MRT (h) 12.2±2.2 7.4± 3.9 6.4±3.3#
TNP-G
T1/2 (h) 6.4±2.7 13.7± 5.7
# 6.3±2.1
Cmax (ng/ml) 227.7±93.5 43.1± 19.3
## 250.6±52.8
AUC(0-t) (ng.h/ml) 488.5±92.2 294.1± 100.1
# 645.1±117.8
MRT (h) 8.4±3.8 19.6± 8.1# 7.1±0.9
Probenecid (200 mg/kg), tariquidar (10 mg/kg), and saline (control) was injected into
caudal vein 15 min prior to the intragastric administration of TNP at a dose of 12 mg/kg.
Data are expressed as mean ± SD (n = 6). #P < 0.05, ##P < 0.01 compared with saline
group.
TABLE 3 | Pharmacokinetic parameters of TNP and TNP-G after
administration of TNP to mice pretreated with siRNA.
TNP TNP + NC-siRNA TNP + mdr1a siRNA
t1/2 (h) 5.1± 1.1 5.1±2.1
Cmax (ng/ml) 38.0± 12.6 211.9±61.3
##
AUC(0-t) (ng.h/ml) 209.64± 40.5 708.6±103.8
##
MRT (h) 4.57± 0.46 3.29±0.28#
TNP-G TNP + NC-siRNA TNP + MRP2 siRNA
t1/2 (h) 4.3± 1.7 6.1±1.1
Cmax (ng/ml) 37.1± 14.9 100.2±17.6
##
AUC(0-t) (ng.h/ml) 108.4± 19.6 202.7±70.7
#
MRT (h) 5.7± 2.0 6.7±1.7
siRNA was injected into caudal vein 2 days prior to the intragastric administration of TNP
at a dose of 12 mg/kg. Data are expressed as mean ± SD (n = 6). #P < 0.05, ##P < 0.01
compared with saline group.
excretion and intestinal reabsorption of a drug, sometimes with
hepatic or intestinal conjugation and intestinal deconjugation
(Roberts et al., 2002). EHC changes the pharmacokinetics of
drugs by influencing T1/2 and AUC (Marier et al., 2002; Xing
et al., 2005). Our previous study confirmed, by using a paired rat
model, that TNP, and TNP-G underwent significant EHC (Deng
et al., 2012). The EHC had a significant effect on the terminal
elimination of TNP, resulting in the prolonged retention of the
drug in rats. The EHC could be benefit to TNP pharmacological
effects. Reduction in biliary excretion and EHC of TNP might
impact the duration of drug action. Furthermore, TNP is a dual
substrate of metabolizing enzymes and P-gp, which undergoes
CYP-mediated oxidative metabolism in the liver (Deng et al.,
2010). Modulations of P-gp by tariquidar or mdr1a siRNA may
increase the exposure of the drug to the metabolizing enzymes
in the liver. The interplay between the drug enzymes and eﬄux
transporter might further complicate the hepatic clearance
of TNP.
In contrast to TNP, the alteration of TNP-G disposition was
contradictory between probenecid group and siRNA treatment
group. In the MRP2 siRNA pretreated mice, the plasma
exposure of TNP-G was remarkably increased, with Cmax
and AUC0-t being 2.7-and 1.9-fold increased, respectively,
when compared to the NC-siRNA group, and the retention
time of the drug (MRT) was significantly reduced. This
was consistent with the changes observed for TNP. In the
probenecid treated group, the T1/2 and MRT of TNP-G
were prolonged, and the Cmax, and AUC0-t were significantly
decreased. TNP-G is a glucoronide metabolite of TNP formed
by UGT1A1 (Dong et al., 2013). As a chemical inhibitor,
probenecid has a dual function on the MRP2 transporter and
drug metabolizing enzymes. Several previous studies showed
the inhibitory effect of probenecid on UGTs (Miners and
Mackenzie, 1991; Uchaipichat et al., 2004). We performed
the in vitro inhibition experiment using rat liver microsomes
and recombinant UGT1A1. However, the results showed that
probenecid had no significant effect on TNP glucuronidation
(Supplementary Table 4). The formation and disposition
of TNP-G in vivo is a complex process involving the
glucuronidation of TNP in the liver and intestine, hepatobiliary
excretion, deconjugation, and reabsorption of the conjugate
in the intestine. Interference in each step of aforementioned
processes may affect the pharmacokinetic profile of TNP-
G. Further investigations are warranted to understand the
mechanisms underlining the interaction between probenecid and
TNP-G.
CONCLUSION
The present study demonstrated the major roles of P-gp and
MRP2 in biliary excretion of TNP and TNP-G, respectively.
Inhibition of P-gp or MRP2 using a chemical inhibitor or siRNA
significantly affected the bile excretion of TNP or TNP-G and
subsequently caused the alteration in pharmacokinetics of the
drug. The potential DDIs of TNP with P-gp or MRP2modulators
should be considered in the treatment of opioid dependence.
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